LIK066

• CAT Number: I007670
• CAS Number: 1291094-73-9
• Molecular Formula: C51H65NO16
• Molecular Weight: 948.072
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: Store at -20°C
• IC50: 22nM
• IUPAC Name: (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• InChI: InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
• InChIKey: XFJAMQQAAMJFGB-ZQGJOIPISA-N
• SMILES: CCC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4

LIK066（Cat No.:I007670） is a bioactive compound that acts as a dual inhibitor of sodium-glucose transporter-1 (SGLT1) and sodium-glucose transporter-2 (SGLT2). It is designed to target both transporters involved in glucose reabsorption in the kidneys and intestines. LIK066 demonstrates potent inhibitory activity, with an IC50 value of 22.0 nM against human SGLT1 and 0.5 nM against human SGLT2. This oral medication has the potential to effectively regulate glucose levels by blocking glucose reabsorption, making it a promising candidate for the treatment of conditions such as diabetes.

Reference

1.Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver. 2014, EMEA-001527-PIP01-13 (here) [ Novartis revealed the IUPAC name here]. 2.Bebernitz, G. R. Glycoside derivatives and their uses for the treatment of diabetes. WO2012140597A1 (synthesis and activity)